HUTCHMED (China) Ltd (NASDAQ: HCM)

HUTCHMED (China) Ltd, often referred to as HCM, is a global commercial-stage biopharmaceutical company with a focus on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Established in 2000, the company's headquarters is located in Hong Kong.

Primarily, HCM generates revenue through the sale of its innovative oncology medicines, including savolitinib, fruquintinib, and surufatinib. These drugs are marketed and distributed through its commercial operations in China and other regions. Additionally, the company generates revenue through partnerships with other biopharmaceutical companies such as AstraZeneca and Takeda.

HUTCHMED's operations span across the oncology commercial and clinical drug development sectors. In the oncology commercial sector, the company markets Fruquintinib (Elunate in China, Fruzaqla in the U.S.), Surufatinib (Sulanda in China), and Savolitinib (Orpathys in China). These drugs have demonstrated impressive sales figures, with in-market sales of $107.5 million, $43.9 million, and $46.1 million respectively in 2023.

In the clinical drug development sector, HUTCHMED has a robust pipeline of innovative oncology medicines. Savolitinib, a selective MET inhibitor, is in late-stage clinical development as a monotherapy and in combination therapies in partnership with AstraZeneca. Fruquintinib, a selective VEGFR 1, 2, and 3 inhibitor, is in global NDA submission and has been commercially launched as Elunate in China and as Fruzaqla in the United States. Surufatinib, a selective CSF-1R inhibitor, is in late-stage clinical development for the treatment of advanced NETs.

HUTCHMED holds a strong position within the industry, boasting a robust pipeline of innovative oncology medicines and strategic partnerships with other biopharmaceutical companies. The company's competitive advantages include its world-class drug discovery engine, comprehensive global in-house discovery and development capabilities, and long-standing drug marketing and distribution experience in China.

HUTCHMED's customers include patients with cancer and immunological diseases, healthcare providers, and payers. The company's drugs are marketed and distributed through its commercial operations in China and other regions.

The company's product portfolio includes savolitinib, fruquintinib, surufatinib, HMPL-306, and HMPL-415. These brands highlight HUTCHMED's commitment to innovation and development in the field of oncology.